Belkin Laser announced that it has completed enrollment in its GLAUrious randomized controlled trial.
In this confirmatory, prospective, non-inferiority, observer-masked RCT, a total of 192 patients were randomized across two arms, SLT and DSLT. 6-month follow-up for primary endpoint is expected in January of 2022 and a 12-month follow-up is expected in Q3 of 2022.
With 140 million people suffering from glaucoma and ocular hypertension worldwide, demand for a first-line dropless treatment for glaucoma far exceeds the ability to treat all patients effectively or at all. Current medical treatments for glaucoma come with low adherence, side effects, and thus are less attractive to the patient. SLT laser treatments currently available on the market are time-intensive, involve contact with the eye, and require specialized skills. Belkin solves all these issues with an automated, gentle treatment that can be completed in seconds, making it a unique treatment solution for both patients and doctors.
“Our disruptive innovation has the potential to significantly expand the treatment options available to glaucoma patients today by providing an intuitive and time-efficient treatment which is unparalleled in its ease of use,” stated Daria Lemann Blumenthal, CEO and co-founder of Belkin Laser. “Conclusion of enrollment is a significant milestone, and we are pleased to see our clinical activities proceed as planned.”